Cardiol Therapeutics Analyst Ratings
Cardiol Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 226.09% | Cantor Fitzgerald | → $3 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 552.17% | Canaccord Genuity | $5 → $6 | Maintains | Buy |
| 12/17/2021 | 769.57% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 12/03/2021 | 769.57% | Canaccord Genuity | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 226.09% | 康託·菲茨傑拉德 | →$3 | 重申 | 超重→超重 |
| 2023年05月19日 | 552.17% | 卡納科特·格納奇 | $5→$6 | 維護 | 買 |
| 2021/12/17 | 769.57% | 康託·菲茨傑拉德 | →$8 | 開始承保 | →超重 |
| 12/03/2021 | 769.57% | 卡納科特·格納奇 | →$8 | 開始承保 | →購買 |
What is the target price for Cardiol Therapeutics (CRDL)?
心臟治療藥物(CRDL)的目標價格是多少？
The latest price target for Cardiol Therapeutics (NASDAQ: CRDL) was reported by Cantor Fitzgerald on August 14, 2023. The analyst firm set a price target for $3.00 expecting CRDL to rise to within 12 months (a possible 226.09% upside). 2 analyst firms have reported ratings in the last year.
坎託·菲茨傑拉德於2023年8月14日報道了心臟治療公司(納斯達克：CRDL)的最新目標價。這家分析公司將目標價定為3美元，預計CRDL將在12個月內上漲至(可能上漲226.09%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Cardiol Therapeutics (CRDL)?
心臟治療公司(CRDL)的最新分析師評級是什麼？
The latest analyst rating for Cardiol Therapeutics (NASDAQ: CRDL) was provided by Cantor Fitzgerald, and Cardiol Therapeutics reiterated their overweight rating.
納斯達克(股票代碼：CRDL)的最新分析師評級由坎託·菲茨傑拉德提供，心臟治療公司重申其增持評級。
When is the next analyst rating going to be posted or updated for Cardiol Therapeutics (CRDL)?
心臟治療(CRDL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cardiol Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cardiol Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與心臟治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。心臟治療公司的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右提供。
Is the Analyst Rating Cardiol Therapeutics (CRDL) correct?
分析師對心臟治療公司(CRDL)的評級正確嗎？
While ratings are subjective and will change, the latest Cardiol Therapeutics (CRDL) rating was a reiterated with a price target of $0.00 to $3.00. The current price Cardiol Therapeutics (CRDL) is trading at is $0.92, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的心臟治療(CRDL)評級被重申，目標價在0.00美元至3.00美元之間。目前心臟治療公司(CRDL)的交易價格為0.92美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。